Role of Clinical Pharmacists in Therapy for Patient with Interstitial Lung Disease Induced by Erlotinib
10.6039/j.issn.1001-0408.2016.17.44
- VernacularTitle:临床药师在厄罗替尼致间质性肺炎患者药物治疗中的作用
- Author:
Yixiu LI
;
Yan LOU
;
Xinjing ZHANG
;
Aizhen XIONG
- Publication Type:Journal Article
- Keywords:
Erlotinib;
Interstitial lung disease;
Radiation therapy;
Clinical pharmacist
- From:
China Pharmacy
2016;27(17):2431-2432,2433
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the role of clinical pharmacists in therapy for patient with interstitial lung disease (ILD) induced by erlotinib. METHODS:Clinical pharmacists participated in the therapy for ILD in a patient receiving erlotinib target treat-ment after thoracic vertebra and lumbar radiation,analyzed the cause of ILD and suggested to stop taking imipenem and cilastatin sodium,fluconazol and erlotinib according to lab indexes and patient’s symptom;took prednisone 30 mg,po,qd,for anti-inflam-mation instead of methylprednisolone;adjusted the dose of prednisone to 40 mg/d,and additionally took Carbocisteine oral solution 10 ml,tid,for improving respiratory symptom;panipenem betamipron 1 g,ivgtt,bid,instead of piperacillin sodium and sulbactam sodium. RESULTS:Physicians adopted the suggestions of clinical pharmacists,and the symptom of anhelation and double pneumo-nia recovered;discharged medication plan was erlotinib 150 mg,po,qd. CONCLUSIONS:The patient with radiation history easily suffers from ILD when using erlotinib,and should use erlotinib carefully in the clinic. Clinical pharmacists participated in drug ther-apy and promote safe and rational use of drugs in the clinic.
